DAWN
Day One Biopharmaceuticals I
NASDAQ · Biotechnology
$11.41
+0.93 (+8.87%)
Open$11.06
Previous Close$10.48
Day High$11.50
Day Low$10.84
52W High$13.20
52W Low$5.64
Volume—
Avg Volume1.99M
Market Cap1.21B
P/E Ratio—
EPS$-1.48
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+393.3% upside
Current
$11.41
$11.41
Target
$56.28
$56.28
$41.40
$56.28 avg
$65.73
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 148.71M | 322.81M | 330.87M |
| Net Income | -108,273,267 | -68,873,512 | -86,473,457 |
| Profit Margin | -72.8% | -21.3% | -26.1% |
| EBITDA | -122,405,978 | -92,549,420 | -89,278,899 |
| Free Cash Flow | — | -81,242,335 | -91,466,852 |
| Rev Growth | — | +3.3% | -3.7% |
| Debt/Equity | — | 0.57 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |